Biotech's Encouraging Phase 2
Gut Microbiome Data «Bodes Well» for Phase 3 Source: Streetwise Reports (3/14/18) H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset.
Not exact matches
Even in IBD patients, who have a very messed up
microbiome (a finding of the American
Gut data), the benefits of antioxidant therapy is well documented (see below studies).
«The newest
data we have is on the infant
gut microbiome: the «good» bacteria in our
guts.
This is a highly limiting factor for research, because it complicates the annotation of
data obtained by molecular techniques, and because it has been shown that
gut microbiomes are to some extent specific to their host, and researchers have been using strains of other origin in mouse models.
To investigate, researchers from the Channing Division of Network Medicine at Brigham and Women's Hospital, led by Amir Bashan, PhD, and Yang - Yu Liu, PhD, analyzed
data from large metagenomic datasets (e.g. the Human
Microbiome Project and Student
Microbiome Project) to look at the dynamics of the
gut, mouth and skin
microbiomes of healthy subjects.
ET: «What this
data analysis pipeline, moreover, creates is motivation to look for similar forms of gene loss in other types of symbioses, such as that between humans and their
gut microbiomes.
Michael Blaut, a microbiologist at the German Institute of Human Nutrition in Potsdam, Germany, says the mouse
data are «believable and remarkable,» but says he has a hard time imagining a mechanism that would account for three compounds as chemically different as aspartame, saccharin, and sucralose leading to the same changes in the
gut microbiome.
«It was the first analysis of the
gut microbiome among a foraging population, and the
data indicated that some of our old longstanding ideas about the differences between «good» and «bad»
gut bacteria needed to be re-evaluated,» she said.
Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that new preclinical
data supporting the development of
microbiome therapeutics for immuno - oncology (leveraging
gut microbiota to impact tumor immunotherapy) 1 will be presented today by Sceneay et al in the late breaking poster session at the 2018 American Association for Cancer Research Annual Meeting (AACR) in Chicago.
The new paper, titled «Using Machine Learning to Identify Major Shifts in Human
Gut Microbiome Protein Family Abundance in Disease,» was presented last month at the IEEE International Conference on Big
Data.
Shows you how your bacterial strains and levels compare to the National Institutes of Health's Human
Microbiome Project
data on
gut bacterial strains
Even in IBD patients, who have a very messed up
microbiome (a finding of the American
Gut data), the benefits of antioxidant therapy is well documented (see below studies).